DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM, no inhibition on DDP8 and DPP9. IC50 value: 15 nM [1] Target: DPP4 inhibitor DBPR108 is an IC50=15 nM DPP IV inhibitor displays a more than 3000-fold selectivity over DPP8 DPP9, FAP and DPP-II. TThe in vivo effects of DBPR108, including inhibition of plasma DPP-IV activity and suppression of blood glucose elevation, were also demonstrated. DBPR108 is a potent, selective, long-acting and safe DPP-IV inhibitor as a potential treatment of type 2 diabetes mellitus.
Molekulargewicht:
324.39
Reinheit:
99.93
CAS Nummer:
[1186426-66-3]
Formel:
C16H25FN4O2
Target-Kategorie:
Dipeptidyl Peptidase
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
